PerkinElmer Stock Price, News & Analysis (NYSE:PKI)

PerkinElmer trades on the New York Stock Exchange (NYSE) under the ticker symbol "PKI."

PerkinElmer declared a quarterly dividend on Thursday, July 25th. Stockholders of record on Friday, October 18th will be given a dividend of $0.07 per share on Friday, November 8th. This represents a $0.28 annualized dividend and a dividend yield of 0.33%. The ex-dividend date of this dividend is Thursday, October 17th. View PerkinElmer's Dividend History.

PerkinElmer, Inc. (NYSE:PKI) announced its quarterly earnings results on Monday, July, 29th. The medical research company reported $1.00 earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of $1.01 by $0.01. The medical research company earned $722.50 million during the quarter, compared to analyst estimates of $729.10 million. PerkinElmer had a net margin of 9.01% and a return on equity of 16.07%. PerkinElmer's quarterly revenue was up 2.7% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.91 earnings per share. View PerkinElmer's Earnings History.

PerkinElmer is scheduled to release their next quarterly earnings announcement on Wednesday, October 30th 2019. View Earnings Estimates for PerkinElmer.

PerkinElmer will be holding an earnings conference call on Wednesday, October 30th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

PerkinElmer updated its FY19 earnings guidance on Monday, July, 29th. The company provided EPS guidance of $4.02-4.07 for the period, compared to the Thomson Reuters consensus estimate of $4.05.

13 Wall Street analysts have issued 12 month target prices for PerkinElmer's stock. Their predictions range from $41.00 to $115.00. On average, they anticipate PerkinElmer's share price to reach $76.86 in the next twelve months. This suggests that the stock has a possible downside of 8.5%. View Analyst Price Targets for PerkinElmer.

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PerkinElmer in the last year. There are currently 8 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for PerkinElmer.

News headlines about PKI stock have been trending somewhat negative on Tuesday, according to InfoTrie Sentiment Analysis. The research group rates the sentiment of media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. PerkinElmer earned a coverage optimism score of -1.7 on InfoTrie's scale. They also assigned press coverage about the medical research company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the next few days. View News Stories for PerkinElmer.

PerkinElmer saw a increase in short interest during the month of September. As of September 30th, there was short interest totalling 5,070,000 shares, an increase of 6.5% from the August 30th total of 4,760,000 shares. Based on an average trading volume of 687,000 shares, the days-to-cover ratio is presently 7.4 days. Currently, 4.6% of the company's shares are sold short. View PerkinElmer's Current Options Chain.

Some companies that are related to PerkinElmer include Thermo Fisher Scientific (TMO), Illumina (ILMN), Agilent Technologies (A), Mettler-Toledo International (MTD), Waters (WAT), Bio-Rad Laboratories (BIO), BIO-TECHNE (TECH), Bruker (BRKR), Charles River Laboratories Intl. (CRL), Cambrex (CBM), Luminex (LMNX), Pacific Biosciences of California (PACB), Fluidigm (FLDM), Harvard Bioscience (HBIO) and aTyr Pharma (LIFE).

Based on aggregate information from My MarketBeat watchlists, some companies that other PerkinElmer investors own include Honeywell International (HON), Thermo Fisher Scientific (TMO), Celgene (CELG), Visa (V), Cisco Systems (CSCO), Illumina (ILMN), NVIDIA (NVDA), Citigroup (C), CVS Health (CVS) and General Electric (GE).

PerkinElmer's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Robecosam AG (0.45%), Artemis Investment Management LLP (0.25%), Boston Trust Walden Corp (0.13%), Assenagon Asset Management S.A. (0.06%), Searle & CO. (0.03%) and Commerzbank Aktiengesellschaft FI (0.03%). Company insiders that own PerkinElmer stock include Alexis P Michas, Andrew Okun, Daniel R Tereau, Deborah A Butters, Frank Anders Wilson, James Corbett, Joel S Goldberg, Nicholas A Lopardo, Patrick J Sullivan, Peter Barrett, Prahlad R Singh and Robert F Friel. View Institutional Ownership Trends for PerkinElmer.

PKI stock was sold by a variety of institutional investors in the last quarter, including State of Michigan Retirement System, First Citizens Bank & Trust Co., Tributary Capital Management LLC, Arcadia Investment Management Corp MI, Artemis Investment Management LLP, Virginia Retirement Systems ET AL, Ascension Asset Management LLC and State of Alaska Department of Revenue. Company insiders that have sold PerkinElmer company stock in the last year include Alexis P Michas, Andrew Okun, Daniel R Tereau, Deborah A Butters, Joel S Goldberg, Nicholas A Lopardo, Patrick J Sullivan, Peter Barrett and Prahlad R Singh. View Insider Buying and Selling for PerkinElmer.

PKI stock was acquired by a variety of institutional investors in the last quarter, including Robecosam AG, Assenagon Asset Management S.A., Boston Trust Walden Corp, Robeco Institutional Asset Management B.V., Moors & Cabot Inc., Searle & CO., Commerzbank Aktiengesellschaft FI and Peddock Capital Advisors LLC. View Insider Buying and Selling for PerkinElmer.

Shares of PKI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of PKI stock can currently be purchased for approximately $83.97.

PerkinElmer has a market capitalization of $9.33 billion and generates $2.78 billion in revenue each year. The medical research company earns $237.93 million in net income (profit) each year or $3.61 on an earnings per share basis. PerkinElmer employs 12,500 workers across the globe.View Additional Information About PerkinElmer.

The official website for PerkinElmer is http://www.perkinelmer.com/.

PerkinElmer's mailing address is 940 WINTER STREET, WALTHAM MA, 02451. The medical research company can be reached via phone at 781-663-6900 or via email at [email protected]